1
|
Christ SM, Breitenstein M, Heesen P, Turner B, Muehlematter UJ, Pohl K, Willmann J, Maurer A, Nagpal SK, Ahmadsei M, Badra Vlaskou E, Looman EL, Heusel AE, Mayinger M, Balermpas P, Wicki A, Andratschke N, Balboni T, Anh Huynh M, Huellner M, Guckenberger M. Clinical management of oligometastatic cancer: Applying multidisciplinary tumor board recommendations in practice. Clin Transl Radiat Oncol 2024; 48:100838. [PMID: 39224662 PMCID: PMC11367634 DOI: 10.1016/j.ctro.2024.100838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2024] [Revised: 08/05/2024] [Accepted: 08/07/2024] [Indexed: 09/04/2024] Open
Abstract
Aims Multidisciplinary tumor boards (MDTs) are an integral part of ensuring high-quality, evidence-based and personalized cancer care. In this study, we aimed to evaluate the adherence to and implementation of MDT recommendations in patients with oligometastatic disease (OMD). Methods We screened all oncologic positron emission tomography (PET) scans conducted at a single comprehensive cancer center in 2020. Patients were included if they had evidence of imaging-based OMD from a solid organ malignancy on the index scans, had their OMD case discussed at an MDT, and were treated and followed up at the same center. A switch away from the MDT-recommended treatment modalities was classified as a major deviation; non-MDT-mandated adjustments to a recommended treatment modality were coded as minor deviation. Clinical data was obtained via chart review; statistical calculations were computed using the R software. Results After review of PET and/or concurrent brain scans, 787 cases of OMD were identified. Thereof, 347 (44.1 %) cases were discussed at MDT, of which 331 (42.1 %) were therapeutically managed and subsequently followed. The three most commonly recommended therapies were systemic therapy (35.6 %), multimodality treatment including definitive local therapy (17.8 %), and radiotherapy (13.9 %). A major deviation was recorded in 16.3 % of cases (most commonly: none of the MDT-recommended treatment modalities were performed: 19 (35.2 %); not all MDT-planned treatment modalities were performed: 12 (22.2 %); and additional treatment modality was performed: 11 (20.3 %). A minor deviation was found in 1.5 % of cases. On multivariable regression, number of distant metastases (n > 1) was associated with a major deviation (OR: 1.85; 95 % CI, 1.0-3.52). Major deviations were associated with a significantly worse OS (p = 0.0034). Conclusions Adherence to and implementation of MDT recommendations in OMD patients was generally high (83.7%). Major deviations might be further reduced by more careful and elaborate discussions of OMD patient characteristics s and patient preferences.
Collapse
Affiliation(s)
- Sebastian M. Christ
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | | | - Philip Heesen
- Faculty of Medicine, University of Zurich, Zurich, CH, Switzerland
| | - Brandon Turner
- Dept. of Radiation Oncology, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Boston, MA, USA
| | - Urs J. Muehlematter
- Dept. of Nuclear Medicine, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Kaspar Pohl
- Faculty of Medicine, University of Zurich, Zurich, CH, Switzerland
| | - Jonas Willmann
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Alexander Maurer
- Dept. of Nuclear Medicine, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | | | - Maiwand Ahmadsei
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Eugenia Badra Vlaskou
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Esmée L. Looman
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Astrid E. Heusel
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Michael Mayinger
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Panagiotis Balermpas
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Andreas Wicki
- Dept. of Medical Oncology & Hematology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Nicolaus Andratschke
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Tracy Balboni
- Dept. of Radiation Oncology, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Boston, MA, USA
| | - Mai Anh Huynh
- Dept. of Radiation Oncology, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Boston, MA, USA
| | - Martin Huellner
- Dept. of Nuclear Medicine, University Hospital & University of Zurich, Zurich, CH, Switzerland
| | - Matthias Guckenberger
- Dept. of Radiation Oncology, University Hospital & University of Zurich, Zurich, CH, Switzerland
| |
Collapse
|
3
|
Wong ML, Gao J, Thanarajasingam G, Sloan JA, Dueck AC, Novotny PJ, Jatoi A, Hurria A, Walter LC, Miaskowski C, Cohen HJ, Wood WA, Feliciano JL, Stinchcombe TE, Wang X. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). Oncologist 2021; 26:e435-e444. [PMID: 32951293 PMCID: PMC7930405 DOI: 10.1002/onco.13527] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 08/27/2020] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Prior comparisons of chemotherapy adverse events (AEs) by age and performance status (PS) are limited by the traditional maximum grade approach, which ignores low-grade AEs and longitudinal changes. MATERIALS AND METHODS To compare fatigue and neuropathy longitudinally by age (<65, ≥65 years) and PS (0-1, 2), we analyzed data from a large phase III trial of carboplatin and paclitaxel versus paclitaxel for advanced non-small cell lung cancer (CALGB 9730, n = 529). We performed multivariable (a) linear mixed models to estimate mean AE grade over time, (b) linear regression to estimate area under the curve (AUC), and (c) proportional hazards models to estimate the hazard ratio of developing grade ≥2 AE, as well as traditional maximum grade analyses. RESULTS Older patients had on average a 0.17-point (95% confidence interval [CI], 0.00-0.34; p = .049) higher mean fatigue grade longitudinally compared with younger patients. PS 2 was associated with earlier development of grade ≥2 fatigue (hazard ratio [HR], 1.56; 95% CI, 1.07-2.27; p = .02). For neuropathy, older age was associated with earlier development of grade ≥2 neuropathy (HR, 1.41; 95% CI, 1.00-1.97; p = .049). Patients with PS 2 had a 1.30 point lower neuropathy AUC (95% CI, -2.36 to -0.25; p = .02) compared with PS 0-1. In contrast, maximum grade analyses only detected a higher percentage of older adults with grade ≥3 fatigue and neuropathy at some point during treatment. CONCLUSION Our comparison of complementary but distinct aspects of chemotherapy toxicity identified important longitudinal differences in fatigue and neuropathy by age and PS that are missed by the traditional maximum grade approach. Clinical trial identification number: NCT00003117 (CALGB 9730) IMPLICATIONS FOR PRACTICE: The traditional maximum grade approach ignores persistent low-grade adverse events (AEs) and changes over time. This toxicity over time analysis of fatigue and neuropathy during chemotherapy for advanced non-small cell lung cancer demonstrates how to use longitudinal methods to comprehensively characterize AEs over time by age and performance status (PS). We identified important longitudinal differences in fatigue and neuropathy that are missed by the maximum grade approach. This new information about how older adults and patients with PS 2 experience these toxicities longitudinally may be used clinically to improve discussions about treatment options and what to expect to inform shared decision making and symptom management.
Collapse
Affiliation(s)
- Melisa L. Wong
- Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San FranciscoSan FranciscoCaliforniaUSA,Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical CenterSan FranciscoCaliforniaUSA
| | - Junheng Gao
- Alliance Statistics and Data Center, Duke UniversityDurhamNorth CarolinaUSA
| | | | - Jeff A. Sloan
- Alliance Statistics and Data Center, Mayo ClinicRochesterMinnesotaUSA
| | - Amylou C. Dueck
- Alliance Statistics and Data Center, Mayo ClinicScottsdaleArizonaUSA
| | | | - Aminah Jatoi
- Division of Medical Oncology, Mayo ClinicRochesterMinnesotaUSA
| | - Arti Hurria
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer CenterDuarteCaliforniaUSA
| | - Louise C. Walter
- Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical CenterSan FranciscoCaliforniaUSA
| | - Christine Miaskowski
- Department of Physiological Nursing, University of California, San FranciscoSan FranciscoCaliforniaUSA
| | - Harvey J. Cohen
- Center for the Study of Aging and Human Development, Duke UniversityDurhamNorth CarolinaUSA
| | - William A. Wood
- Lineberger Comprehensive Cancer Center, Division of Hematology/Oncology, University of North Carolina, Chapel HillChapel HillNorth CarolinaUSA
| | - Josephine L. Feliciano
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical CenterBaltimoreMarylandUSA
| | | | - Xiaofei Wang
- Alliance Statistics and Data Center, Duke UniversityDurhamNorth CarolinaUSA
| |
Collapse
|
5
|
Santos FN, de Castria TB, Cruz MRS, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Cochrane Database Syst Rev 2015; 2015:CD010463. [PMID: 26482542 PMCID: PMC6759539 DOI: 10.1002/14651858.cd010463.pub2] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND Approximately 50% of patients with newly diagnosed non-small cell lung cancer (NSCLC) are over 70 years of age at diagnosis. Despite this fact, these patients are underrepresented in randomized controlled trials (RCTs). As a consequence, the most appropriate regimens for these patients are controversial, and the role of single-agent or combination therapy is unclear. In this setting, a critical systematic review of RCTs in this group of patients is warranted. OBJECTIVES To assess the effectiveness and safety of different cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIB and IV) NSCLC. To also assess the impact of cytotoxic chemotherapy on quality of life. SEARCH METHODS We searched the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 10), MEDLINE (1966 to 31 October 2014), EMBASE (1974 to 31 October 2014), and Latin American Caribbean Health Sciences Literature (LILACS) (1982 to 31 October 2014). In addition, we handsearched the proceedings of major conferences, reference lists from relevant resources, and the ClinicalTrial.gov database. SELECTION CRITERIA We included only RCTs that compared non-platinum single-agent therapy versus non-platinum combination therapy, or non-platinum therapy versus platinum combination therapy in patients over 70 years of age with advanced NSCLC. We allowed inclusion of RCTs specifically designed for the elderly population and those designed for elderly subgroup analyses. DATA COLLECTION AND ANALYSIS Two review authors independently assessed search results, and a third review author resolved disagreements. We analyzed the following endpoints: overall survival (OS), one-year survival rate (1yOS), progression-free survival (PFS), objective response rate (ORR), major adverse events, and quality of life (QoL). MAIN RESULTS We included 51 trials in the review: non-platinum single-agent therapy versus non-platinum combination therapy (seven trials) and non-platinum combination therapy versus platinum combination therapy (44 trials). Non-platinum single-agent versus non-platinum combination therapy Low-quality evidence suggests that these treatments have similar effects on overall survival (hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.72 to 1.17; participants = 1062; five RCTs), 1yOS (risk ratio (RR) 0.88, 95% CI 0.73 to 1.07; participants = 992; four RCTs), and PFS (HR 0.94, 95% CI 0.83 to 1.07; participants = 942; four RCTs). Non-platinum combination therapy may better improve ORR compared with non-platinum single-agent therapy (RR 1.79, 95% CI 1.41 to 2.26; participants = 1014; five RCTs; low-quality evidence).Differences in effects on major adverse events between treatment groups were as follows: anemia: RR 1.10, 95% 0.53 to 2.31; participants = 983; four RCTs; very low-quality evidence; neutropenia: RR 1.26, 95% CI 0.96 to 1.65; participants = 983; four RCTs; low-quality evidence; and thrombocytopenia: RR 1.45, 95% CI 0.73 to 2.89; participants = 914; three RCTs; very low-quality evidence. Only two RCTs assessed quality of life; however, we were unable to perform a meta-analysis because of the paucity of available data. Non-platinum therapy versus platinum combination therapy Platinum combination therapy probably improves OS (HR 0.76, 95% CI 0.69 to 0.85; participants = 1705; 13 RCTs; moderate-quality evidence), 1yOS (RR 0.89, 95% CI 0.82 to 0.96; participants = 813; 13 RCTs; moderate-quality evidence), and ORR (RR 1.57, 95% CI 1.32 to 1.85; participants = 1432; 11 RCTs; moderate-quality evidence) compared with non-platinum therapies. Platinum combination therapy may also improve PFS, although our confidence in this finding is limited because the quality of evidence was low (HR 0.76, 95% CI 0.61 to 0.93; participants = 1273; nine RCTs).Effects on major adverse events between treatment groups were as follows: anemia: RR 2.53, 95% CI 1.70 to 3.76; participants = 1437; 11 RCTs; low-quality evidence; thrombocytopenia: RR 3.59, 95% CI 2.22 to 5.82; participants = 1260; nine RCTs; low-quality evidence; fatigue: RR 1.56, 95% CI 1.02 to 2.38; participants = 1150; seven RCTs; emesis: RR 3.64, 95% CI 1.82 to 7.29; participants = 1193; eight RCTs; and peripheral neuropathy: RR 7.02, 95% CI 2.42 to 20.41; participants = 776; five RCTs; low-quality evidence. Only five RCTs assessed QoL; however, we were unable to perform a meta-analysis because of the paucity of available data. AUTHORS' CONCLUSIONS In people over the age of 70 with advanced NSCLC who do not have significant co-morbidities, increased survival with platinum combination therapy needs to be balanced against higher risk of major adverse events when compared with non-platinum therapy. For people who are not suitable candidates for platinum treatment, we have found low-quality evidence suggesting that non-platinum combination and single-agent therapy regimens have similar effects on survival. We are uncertain as to the comparability of their adverse event profiles. Additional evidence on quality of life gathered from additional studies is needed to help inform decision making.
Collapse
Affiliation(s)
- Fábio N Santos
- AC Camargo Cancer CenterMedical OncologyRua Prof. Antonio Prudente, 211São PauloSão PauloBrazil01509‐900
| | - Tiago B de Castria
- Instituto do Câncer do Estado de São Paulo (ICESP/FMUSP)Medical OncologyAv. Doutor Arnaldo 251 ‐ Cerqueira CésarSão PauloBrazil01246‐000
| | - Marcelo RS Cruz
- Beneficencia Portuguesa de São PauloMedical OncologyRua Martiniano de Carvalho951São PauloSão PauloBrazil013023001
| | - Rachel Riera
- Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em SaúdeCochrane BrazilRua Borges Lagoa, 564 cj 63São PauloSPBrazil04038‐000
| | | |
Collapse
|
6
|
Bakogeorgos M, Mountzios G, Bournakis E, Economopoulou P, Kotsantis G, Fytrakis N, Kouvatseas G, Dimopoulos MA, Kentepozidis N. Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece. J Geriatr Oncol 2014; 6:111-8. [PMID: 25482021 DOI: 10.1016/j.jgo.2014.11.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 09/06/2014] [Accepted: 11/07/2014] [Indexed: 11/16/2022]
Abstract
BACKGROUND Elderly patients with advanced non-small cell lung cancer (NSCLC) are thought to receive suboptimal treatment mainly due to concerns for poor compliance and/or excessive toxicity. PATIENTS AND METHODS Using the age of 70 years as the pre-defined cut-off, we compared elderly patients with advanced NSCLC suitable for first line chemotherapy with their younger counterparts in terms of: i) diagnosis and disease characteristics ii) adherence to treatment schedule, including dose intensity (DI), and relative dose intensity (RDI), iii) toxicity, tolerance, and efficacy outcomes. RESULTS Among 292 eligible patients, data were available for 245, of whom 107 (43.7%) belonged to the elderly group. This group was more likely to present with co-morbidities, non-smoking current status and diagnosis based on cytology alone. As compared to the non-elderly, elderly patients were more likely to receive single-agent therapy (8.0% vs. 29.2% respectively, p < 0.001) and less likely to receive platinum-based chemotherapy (80.3% vs. 57.9%, p < 0.001). Elderly patients also received docetaxel (24.3% vs. 40.4%), and bevacizumab (7.5% vs. 21.3%) significantly less often and received oral vinorelbine (24.3% vs. 11.8%) more frequently. Non-elderly patients were more likely to receive any of the cytotoxic drugs with RDI > 0.8 (49.6% vs. 33.0%, p = 0.012) and RDI > 0.9 (29.6% vs. 16%, p = 0.015). Substantial toxicity, as well as median overall survival did not differ significantly between the two groups. CONCLUSIONS Only one third of the elderly patients received at least 80% of the scheduled treatment intensity. Nearly half received diagnosis based on cytology alone, which may deprive them from new, histology-driven, therapeutic approaches.
Collapse
Affiliation(s)
- Marios Bakogeorgos
- 251 Airforce General Hospital, Department of Medical Oncology, Athens, Greece; "Alexandra" University Hospital, Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
| | - Giannis Mountzios
- 251 Airforce General Hospital, Department of Medical Oncology, Athens, Greece; "Alexandra" University Hospital, Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
| | - Evangelos Bournakis
- "Alexandra" University Hospital, Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
| | | | - Giannis Kotsantis
- 251 Airforce General Hospital, Department of Medical Oncology, Athens, Greece
| | - Nikolaos Fytrakis
- 251 Airforce General Hospital, Department of Medical Oncology, Athens, Greece
| | | | - Meletios-Athanassios Dimopoulos
- "Alexandra" University Hospital, Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
| | | |
Collapse
|
10
|
Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, Curigliano G, Extermann M, Lichtman SM, Ballman K, Cohen HJ, Muss H, Wedding U. End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article. J Clin Oncol 2013; 31:3711-8. [DOI: 10.1200/jco.2013.49.6125] [Citation(s) in RCA: 229] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Selecting the most appropriate end points for clinical trials is important to assess the value of new treatment strategies. Well-established end points for clinical research exist in oncology but may not be as relevant to the older cancer population because of competing risks of death and potentially increased impact of therapy on global functioning and quality of life. This article discusses specific clinical end points and their advantages and disadvantages for older individuals.Randomized or single-arm phase II trials can provide insight into the range of efficacy and toxicity in older populations but ideally need to be confirmed in phase III trials, which are unfortunately often hindered by the severe heterogeneity of the older cancer population, difficulties with selection bias depending on inclusion criteria, physician perception, and barriers in willingness to participate. All clinical trials in oncology should be without an upper age limit to allow entry of eligible older adults. In settings where so-called standard therapy is not feasible, specific trials for older patients with cancer might be required, integrating meaningful measures of outcome. Not all questions can be answered in randomized clinical trials, and large observational cohort studies or registries within the community setting should be established (preferably in parallel to randomized trials) so that treatment patterns across different settings can be compared with impact on outcome. Obligatory integration of a comparable form of geriatric assessment is recommended in future studies, and regulatory organizations such as the European Medicines Agency and US Food and Drug Administration should require adequate collection of data on efficacy and toxicity of new drugs in fit and frail elderly subpopulations.
Collapse
Affiliation(s)
- Hans Wildiers
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Murielle Mauer
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Athanasios Pallis
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Arti Hurria
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Supriya G. Mohile
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Andrea Luciani
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Giuseppe Curigliano
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Martine Extermann
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Stuart M. Lichtman
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Karla Ballman
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Harvey Jay Cohen
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Hyman Muss
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| | - Ulrich Wedding
- Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels; Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland; Arti Hurria, City of Hope, Duarte, CA; Arti Hurria, Karla Ballman, Harvey Jay Cohen,
| |
Collapse
|